PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors

被引：9
|
作者：
Minari, Roberta [1 ]
Bonatti, Francesco [1 ]
Mazzaschi, Giulia [1 ,2 ]
Dodi, Alessandra [2 ]
Facchinetti, Francesco [1 ,3 ]
Gelsomino, Francesco [4 ]
Cinquegrani, Gloria [2 ]
Squadrilli, Anna [1 ]
Bordi, Paola [1 ]
Buti, Sebastiano [1 ]
Bersanelli, Melissa [1 ]
Leonetti, Alessandro [1 ]
Cosenza, Agnese [1 ]
Ferri, Leonarda [1 ]
Rapacchi, Elena [1 ]
Quaini, Federico [2 ]
Ardizzoni, Andrea [4 ]
Tiseo, Marcello [1 ,2 ]
机构：
[1] Univ Hosp Parma, Med Oncol Unit, Via Gramsci 14, I-43126 Parma, Italy
[2] Univ Parma, Dept Med & Surg, Parma, Italy
[3] Univ Paris Saclay, Inst Gustave Roussy, Biomarqueurs Predictifs & Nouvelles Strategies Th, INSERM, Villejuif, France
[4] AOU Policlin S Orsola Malpighi, Med Oncol, Bologna, Italy
来源：
TUMORI JOURNAL | 2022年 / 108卷 / 01期
关键词：
NSCLC; immunotherapy; PD-L1; SNPs; biomarker; CELL LUNG-CANCER; POLYMORPHISMS; ASSOCIATION; NIVOLUMAB; DOCETAXEL; EXPRESSION; PROGNOSIS; GENE;
D O I：
10.1177/03008916211014954
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objective: To investigate the role of CTLA-4, PD-1 (programmed death-1), and PD-L1 (programmed death-ligand 1) single nucleotide polymorphisms (SNPs) in predicting clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). Methods: A total of 166 consecutive patients were included. We correlated SNPs with clinical benefit, progression-free survival, time to treatment failure, and overall survival and evaluated the incidence of SNPs in nonresponder and long clinical benefit groups. Results: Considering the entire cohort, no correlation was found between SNPs and clinical outcome; however, PD-L1 rs4143815 SNP and the long clinical benefit group showed a statistically significant association (p = 0.02). The nonresponder cohort displayed distinctive PD-L1 haplotype (p = 0.05). Conclusion: PD-L1 SNPs seem to be marginally involved in predicting clinical outcome of NSCLC treated with ICI, but further investigations are required.
引用
收藏
页码：47 / 55
页数：9
相关论文
共 50 条
  • [1] Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors
    Castello, A.
    Rossi, S.
    Toschi, L.
    Lopci, E.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S66 - S67
  • [2] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Higashijima, Naoko
    Matsuo, Norikazu
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (08) : 2829 - 2840
  • [3] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Hidetomo Himuro
    Yoshiro Nakahara
    Yuka Igarashi
    Taku Kouro
    Naoko Higashijima
    Norikazu Matsuo
    Shuji Murakami
    Feifei Wei
    Shun Horaguchi
    Kayoko Tsuji
    Yasunobu Mano
    Haruhiro Saito
    Koichi Azuma
    Tetsuro Sasada
    [J]. Cancer Immunology, Immunotherapy, 2023, 72 : 2829 - 2840
  • [4] Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors
    Nakahara, Y.
    Himuro, H.
    Igarashi, Y.
    Kouro, T.
    Higashijima, N.
    Matsuo, N.
    Murakami, S.
    Wei, F.
    Horaguchi, S.
    Tsuji, K.
    Mano, Y.
    Saito, H.
    Azuma, K.
    Naoki, K.
    Sasada, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S614 - S614
  • [5] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
  • [6] Single nucleotide polymorphisms (SNPs) in PD-L1 as predictive biomarkers for checkpoint inhibitor based-immunotherapy in caucasian patients with advanced NSCLC
    Sabbatino, Francesco
    Polcaro, Giovanna
    Liguori, Luigi
    Manzo, Valentina
    Conti, Valeria
    Dal Col, Jessica
    Vergatti, Anita
    Stellato, Cristiana
    Casolaro, Vincenzo
    Filippelli, Amelia
    Ferrone, Soldano
    Pepe, Stefano
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [7] Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters
    Castello, Angelo
    Rossi, Sabrina
    Toschi, Luca
    Mansi, Luigi
    Lopci, Egesta
    [J]. CANCERS, 2020, 12 (06)
  • [8] Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression.
    Aguiar, Pedro Nazareth
    Tadokoro, Hakaru
    Barreto, Carmelia Maria Noia
    Santoro, Ilka Lopes
    De Mello, Ramon Andrade
    Babiker, Hani M.
    Avancha, Kiran
    Lopes, Gilberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression
    Aguiar, Pedro, Jr.
    Perry, Luke A.
    Lopes, Gilberto L., Jr.
    [J]. LUNG CANCER MANAGEMENT, 2016, 5 (03) : 119 - 122
  • [10] Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors
    Maiorano, Brigida Anna
    Di Maio, Massimo
    Cerbone, Linda
    Maiello, Evaristo
    Procopio, Giuseppe
    Roviello, Giandomenico
    [J]. JAMA NETWORK OPEN, 2024, 7 (03) : E241215
12345